1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Time Is On Eisai’s Side As More Long-Term Data Emerge For Leqembi

Dual Action Stands Out From Lilly’s Kisunla

 
• By Mandy Jackson

Leqembi for early Alzheimer’s disease now has an anti-amyloid competitor in the US with limited-term dosing, but new data at AAIC support chronic dosing of Eisai’s Biogen-partnered drug.

Caregiver cheers up senior lady patient touching hand while sits in armchairs in light room
Maintenance and subcutaneous dosing could reduce the burden of chronic Leqembi treatment • Source: Shutterstock

New long-term data on Eisai Co., Ltd./Biogen, Inc.’s early Alzheimer’s disease medicine Leqembi (lecanemab) presented at the Alzheimer’s Association International Conference (AAIC) indicate that chronic treatment has a better effect than short-term treatment, possibly negating what was thought to be a potential advantage for Eli Lilly and Company’s competing anti-amyloid antibody Kisunla (donanemab).

Key Takeaways

  • Eisai and Biogen have a first-to-market advantage in early Alzheimer’s disease with Leqembi, but a second anti-amyloid antibody has reached the market from Lilly with potential dosing advantages.

Leqembi has been on the market in the US since receiving accelerated approval in January 2023, giving it a year...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

 
• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

More from R&D

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

Pipeline Watch: Eight Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.